Flashback Foreword: Cytoreductive Surgery for Ovarian Carcinoma and Carboplatin + Paclitaxel in Ovarian Cancer
Authors: David R. Spriggs, Gini F. Fleming
Journal: Journal of Clinical Oncology (2023)

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis. August 29, 2023 Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study. August 29, 2023 ARTICLE CITATION DOI: 10.1200/JCO.23.00102 Journal of Clinical Oncology - published online before print August 29, 2023 Flashback Foreword: Cytoreductive Surgery for Ovarian Carcinoma and Carboplatin + Paclitaxel in Ovarian Cancer David R. Spriggs, MD1,2xDavid R. SpriggsSearch for articles by this author and Gini F. Fleming , MD3,4xGini F. FlemingSearch for articles by this author Show More 1Former Associate Editor, Journal of Clinical Oncology, Alexandria, VA2MGH and Harvard Medical School, Boston, MA3Associate Editor, Journal of Clinical Oncology, Alexandria, VA4University of Chicago, Chicago, IL https://doi.org/10.1200/JCO.23.00102 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: All authorsCollection and assembly of data: David R. SpriggsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Cytoreductive Surgery for Ovarian Carcinoma and Carboplatin + Paclitaxel in Ovarian CancerThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).David R. SpriggsLeadership: Repertoire Immune MedicinesConsulting or Advisory Role: Brahma Therapeutics, Repertoire Immune MedicinesSpeakers' Bureau: Brahma TherapeuticsPatents, Royalties, Other Intellectual Property: Through my laboratory, we have discovered anti-MUC16 antibodies that MSKCC has filed patents about. These patents, if commercialized, could ultimately result in royalties paid to me (Inst)Gini F. FlemingThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Honoraria: Physicians' Education ResourceResearch Funding: Corcept Therapeutics (Inst), AbbVie (Inst), Iovance Biotherapeutics (Inst), Syros Pharmaceuticals (Inst), Sermonix Pharmaceuticals (Inst), Compugen (Inst), Plexxikon (Inst), Roche (Inst), GlaxoSmithKline (Inst), Celldex (Inst), AstraZeneca (Inst), Molecular Templates (Inst), CytomX Therapeutics (Inst), Astellas Pharma (Inst), K-Group Beta (Inst), Pfizer (Inst), Merck (Inst), Incyte (Inst)Other Relationship: DSI (Inst), Merck (Inst), Caris Life Sciences (Inst), Eisai (Inst), AstraZeneca (Inst)Uncompensated Relationships: AbbVieNo other potential conflicts of interest were reported. Companion Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study